BOSTON (GenomeWeb News) — Oxford Gene Technology has closed one of its business units as it concentrates on developing and launching new microarray products and growing its licensing revenue in newer markets like Japan, according to a company official.
 
OGT's CEO Mike Evans said this week that OGT had decided to close down the unit, called Tridend, because it "didn't fit with OGT's core strategy." Evans spoke with GenomeWeb News at IBC Life Sciences' Discovery 2 Diagnostics conference, held here this week.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.